ASCO 2023 | Assessing PARP inhibition and BRCA1/2 as a prognostic biomarker in mCRPC

David James VanderWeele, MD, PhD, Feinberg School of Medicine, Chicago, IL, provides an overvire of multiple studies assessing DDR and PARP inhibition in patients with prostate cancer. One abstract revealed BRCA1/2 and HRR genes are the most important prognostic biomarkers, and molecular testing is highly recommended. The Phase III TALAPRO-2 trial (NCT03395197) of talazoparib plus enzalutamide versus enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) reinforced the utility of BRCA1/2 as a predicative biomarker. The Phase I LuPARP trial (NCT03874884) demonstrated the safety of olaparib with 177Lu-PSMA-617 in mCRPC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.